Nurse Practitioner in Liberty, NC Accepting Medicare
5 Nurse Practitioner nurses found. Showing 1 - 5
 Ashley Brooke Crutchfield, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 525 W Swannanoa Ave, Liberty, NC 27298 Phone: 336-622-4850 Fax: 336-622-4855 |
Caroline E Baugess, NP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 504 N Greensboro St, Liberty, NC 27298 Phone: 336-622-4850 Fax: 336-622-4855 |
Cheryl Jean Wells, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 129 S Fayetteville St, Liberty, NC 27298 Phone: 336-301-8899 |
Breana Frantz, Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 246 W Swannanoa Ave, Liberty, NC 27298 Phone: 336-795-7016 |
Lynn Elizabeth Lam, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 504 N Greensboro St, Liberty, NC 27298 Phone: 336-622-4850 Fax: 336-622-4855 |
News Archive
Periodontal examination can determine risk of diabetes
A recent study published in the Journal of Dental Research at Columbia University College of Dental Medicine (CDM) and backed by The Jeffrey Epstein VI Foundation amongst others; found that a pre-diabetes determination can be made by simply going to the dentist.
Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010
Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Connecticut first state to require paid sick time
The measure, which was signed into law Tuesday by the governor, will benefit - say its backers - between 200,000 and 300,000 workers. Its opponents argue the requirement will make the state less competitive. In related news, Denver voters could consider a similar measure on the November ballot.
Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
Tropical storms likely to become more deadly under climate change, research shows
Tropical storms are likely to become more deadly under climate change, leaving people in developing countries, where there may be a lack of resources or poor infrastructure, at increased risk, new research from Oregon State University shows.
› Verified 2 days ago